Skip to main content
OpenTrials

Clinical trial condition

Plexiform Neurofibroma

Explore clinical trials studying Plexiform Neurofibroma. Study availability and eligibility vary by location and protocol.

17 public trials 2 recruiting studies
Refine in advanced search Browse all conditions

Plexiform Neurofibroma trial results

Recruiting

Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas

NCT06502171

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, +17 more
Locations
  • Childrens of Alabama Birmingham, Alabama, United States
  • Children's National Hospital Washington D.C., District of Columbia, United States
  • Boston Children's Hospital Boston, Massachusetts, United States
  • Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States
View Trial Details
Recruiting

Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1

NCT06188741

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, +17 more
Locations
  • Childrens of Alabama Birmingham, Alabama, United States
  • Children's Hospital of Los Angeles Los Angeles, California, United States
  • Stanford University Palo Alto, California, United States
  • Children's National Hospital Washington D.C., District of Columbia, United States
View all 15 locations
View Trial Details
Active, not recruiting

MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

NCT03962543

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, +18 more
Locations
  • University of Alabama at Birmingham/Children's of Alabama Birmingham, Alabama, United States
  • Mayo Clinic Arizona Phoenix, Arizona, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Children's Hospital Los Angeles Los Angeles, California, United States
View all 43 locations
View Trial Details
Active, not recruiting

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

NCT03363217

Conditions
Brain Diseases, Brain Neoplasms, Central Nervous System Diseases, +29 more
Locations
  • Alberta Children's Hospital Calgary, Alberta, Canada
  • Children and Women's Health Centre of British Colombia Vancouver, British Columbia, Canada
  • IWK Health Centre Halifax, Nova Scotia, Canada
  • The Hospital for Sick Children Toronto, Ontario, Canada
View Trial Details
Active, not recruiting

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas

NCT05913037

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, +18 more
Locations
  • Cancer Hospital Chinese Academy of Medical Sciences Beijing, Beijing Municipality, China
  • Chinese Academy of Medical Sciences & Peking Union Medical College Beijing, Beijing Municipality, China
  • Plastic Surgery Hospital,Chinese Academy of Medical Sciences Beijing, Beijing Municipality, China
  • Nanfang Hospital, Southern Medical University Guangzhou, Guangdong, China
View all 15 locations
View Trial Details
Active, not recruiting

Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

NCT04954001

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, +18 more
Locations
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • Principal Investigator Hans Gainesville, Florida, United States
  • John Hopkins All Children Hospital St. Petersburg, Florida, United States
  • Henry Ford Health System Detroit, Michigan, United States
View all 14 locations
View Trial Details

Related conditions